바이오정보모아 (BioJungboMoa) — ADC · Antibody

8428프로그램 40FDA 승인

1,921오늘 방문

8,955누적 방문

7303갱신 대기 S–CData Tier S/A/B차세대 →Insight 1032HER2 breast 4683Antibody 2713CGT →Psoriasis →NSCLC 40FDA 승인

피드 Data Tier 차세대 Insight

pembrolizumab (Keytruda, Tebentafusp with Pembrolizumab)

Advanced Melanoma · Advanced Melanoma

#AdvancedMelanoma#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 RECRUITING

CGTBiologicstaleChinese PLA General HospitalPhase 2

TCR reserved and Power3 (SPPL3, TCR reserved and Power3, TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell)

Acute Lymphocytic Leukemia · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) peptide vaccine)

Prostate Specific Antigens; Prostate Neoplasms · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 ACTIVE

ADCBiologicstaleNEOK Bio, Inc.Phase 1

NEOK001 RDE (NEOK001 RDE)

Locally Advanced (Unresectable) or Metastatic Solid Tumors · Locally Advanced (Unresectable) or Metas

#LocallyAdvancedUnresectableorMet#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

ADCBiologicstaleLigaChem Biosciences, Inc.Phase 2

LCB84 (LCB84)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

ADCBiologicstaleCancer Institute and Hospital, …Phase 2

Almonertinib/Furmonertinib/Osimertinib (third-generation EGFR TKIs, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib))

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · EGFR

#EGFR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 1상태 RECRUITING

CGTBiologicstaleCancer Institute and Hospital, …Phase 1

anti-PSMA CAR-NK (anti-PSMA CAR-NK)

Prostate Cancer Castration-resistant Prostate Cancer · PSMA

#PSMA#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleSun Yat-sen UniversityPhase 1

LMP2 Antigen-specific TCR T cells (LMP2 Antigen-specific TCR T cells)

Nasopharyngeal Carcinoma · Nasopharyngeal Carcinoma

#NasopharyngealCarcinoma#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Docetetaxel (Docetetaxel)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 1상태 RECRUITING

CGTBiologicstaleShanghai Cell Therapy Research …Phase 2

anti-CTLA-4/PD-1 expressing EGFR-CAR-T (anti-CTLA-4/PD-1 expressing EGFR-CAR-T)

Advanced Solid Tumor · EGFR

#EGFR#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTBiologicstaleUniversity of California, San F…Phase 1

Autologous Anti-H3.3K27M TCR-expressing T-cells (Autologous Anti-H3.3K27M TCR-expressing T-cells)

Diffuse Midline Glioma, H3 K27M-Mutant · Diffuse Midline Glioma, H3 K27M-Mutant

#DiffuseMidlineGliomaH3K27M-Mutan#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

ADCBiologicstaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 1상태 RECRUITING

AntibodystaleRochePhase 1

bevacizumab, reference product (Avastin®, Avastin® (bevacizumab, reference product))

Metastatic Colorectal Cancer (mCRC) · Metastatic Colorectal Cancer (mCRC)

#MetastaticColorectalCancermCRC#Antibody#Phase1#항체#면역항체+2

효능 ORR 5%임상시험 1상태 ACTIVE

CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Multi-epitope (ME, Multi-epitope, Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine)

Prostatic Neoplasms; Prostate Cancer · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

효능 ORR 2.4%임상시험 1상태 DISCONTINUED

CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

E7 TCR cells (E7 TCR cells)

Papillomavirus Infections; Cervical Intraepithelial Neoplasia · Papillomavirus Infections

#PapillomavirusInfections#CGT#Phase2#세포유전치료#CAR-T+3

효능 ORR 5%임상시험 1상태 ACTIVE

CGTBiologicstaleCell Medica LtdPhase 2

Autologous WT1 TCR transduced T cells (Autologous WT1 TCR transduced T cells)

Myelodysplastic Syndromes (MDS); Acute Myeloid Leukaemia (AML) · Myelodysplastic Syndromes (MDS)

#MyelodysplasticSyndromesMDS#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

AntibodystaleEli LillyPhase 2

Capecitabine, Cetuximab, Oxaliplatin (Capecitabine, Cetuximab, Oxaliplatin)

Rectal Cancer · Rectal Cancer

#RectalCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleJanssenApproved

ustekinumab (Stelara, 1: filgotinib 2: ustekinumab 3: vedolizumab 4: infliximab))

Ulcerative Colitis (UC) · Ulcerative Colitis (UC)

#UlcerativeColitisUC#Antibody#Approved#항체#면역항체+2

임상시험 1상태 RECRUITING

CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Preclinical

CT0590 CAR T Cells (CT0590 CAR T Cells)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+4

임상시험 1상태 ACTIVE

ADCBiologicstaleVelaVigo Bio IncPhase 2

VBC101 (VBC101)

Participants With Advanced Solid Tumor Malignancies · Participants With Advanced Solid Tumor M

#ParticipantsWithAdvancedSolidTum#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

CGTBiologicstaleGuenther KoehnePhase 1

T-cell Receptor α/β Depleted Donor Lymphocyte Infusions (T-cell Receptor α/β Depleted Donor Lymphocyte Infusions)

Lymphoid Leukemia, Acute; Myeloid Malignancy · Lymphoid Leukemia, Acute

#LymphoidLeukemiaAcute#CGT#Phase1#세포유전치료#CAR-T+5

임상시험 1상태 DISCONTINUED

CGTBiologicstaleAnhui Provincial HospitalPhase 1

QH101 (Allogeneic TCR-enhanced γδ T cell, Allogeneic TCR-enhanced γδ T cell(QH101))

MDS; AML · MDS

#MDS#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleBristol-Myers SquibbPhase 1

IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells (IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells)

Recurrent Glioblastoma; Refractory Glioblastoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

ADCBiologicstaleDaiichi SankyoPhase 1

DS-1103a (DS-1103a)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

CGTBiologicstaleThe Affiliated Hospital of Qing…Phase 1

SCG142 TCR-T cells (SCG142 TCR-T cells)

Human Papillomavirus Associated Carcinomas; Cervical Cancer · Human Papillomavirus Associated Carcinom

#HumanPapillomavirusAssociatedCar#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

68 / 142 페이지

← 이전 다음 →

전체 8,428개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 1,921 / 8,955

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

빠른 검색 · 이슈 태그

pembrolizumab (Keytruda, Tebentafusp with Pembrolizumab)

TCR reserved and Power3 (SPPL3, TCR reserved and Power3, TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell)

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) peptide vaccine)

NEOK001 RDE (NEOK001 RDE)

LCB84 (LCB84)

Almonertinib/Furmonertinib/Osimertinib (third-generation EGFR TKIs, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib))

anti-PSMA CAR-NK (anti-PSMA CAR-NK)

LMP2 Antigen-specific TCR T cells (LMP2 Antigen-specific TCR T cells)

Docetetaxel (Docetetaxel)

anti-CTLA-4/PD-1 expressing EGFR-CAR-T (anti-CTLA-4/PD-1 expressing EGFR-CAR-T)

Autologous Anti-H3.3K27M TCR-expressing T-cells (Autologous Anti-H3.3K27M TCR-expressing T-cells)

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

bevacizumab, reference product (Avastin®, Avastin® (bevacizumab, reference product))

Multi-epitope (ME, Multi-epitope, Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine)

E7 TCR cells (E7 TCR cells)

Autologous WT1 TCR transduced T cells (Autologous WT1 TCR transduced T cells)

Capecitabine, Cetuximab, Oxaliplatin (Capecitabine, Cetuximab, Oxaliplatin)

ustekinumab (Stelara, 1: filgotinib 2: ustekinumab 3: vedolizumab 4: infliximab))

CT0590 CAR T Cells (CT0590 CAR T Cells)

VBC101 (VBC101)

T-cell Receptor α/β Depleted Donor Lymphocyte Infusions (T-cell Receptor α/β Depleted Donor Lymphocyte Infusions)

QH101 (Allogeneic TCR-enhanced γδ T cell, Allogeneic TCR-enhanced γδ T cell(QH101))

IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells (IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells)

DS-1103a (DS-1103a)

SCG142 TCR-T cells (SCG142 TCR-T cells)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

pembrolizumab (Keytruda, Tebentafusp with Pembrolizumab)

TCR reserved and Power3 (SPPL3, TCR reserved and Power3, TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell)

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) peptide vaccine)

NEOK001 RDE (NEOK001 RDE)

LCB84 (LCB84)

Almonertinib/Furmonertinib/Osimertinib (third-generation EGFR TKIs, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib))

anti-PSMA CAR-NK (anti-PSMA CAR-NK)

LMP2 Antigen-specific TCR T cells (LMP2 Antigen-specific TCR T cells)

Docetetaxel (Docetetaxel)

anti-CTLA-4/PD-1 expressing EGFR-CAR-T (anti-CTLA-4/PD-1 expressing EGFR-CAR-T)

Autologous Anti-H3.3K27M TCR-expressing T-cells (Autologous Anti-H3.3K27M TCR-expressing T-cells)

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

bevacizumab, reference product (Avastin®, Avastin® (bevacizumab, reference product))

Multi-epitope (ME, Multi-epitope, Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine)

E7 TCR cells (E7 TCR cells)

Autologous WT1 TCR transduced T cells (Autologous WT1 TCR transduced T cells)

Capecitabine, Cetuximab, Oxaliplatin (Capecitabine, Cetuximab, Oxaliplatin)

ustekinumab (Stelara, 1: filgotinib 2: ustekinumab 3: vedolizumab 4: infliximab))

CT0590 CAR T Cells (CT0590 CAR T Cells)

VBC101 (VBC101)

T-cell Receptor α/β Depleted Donor Lymphocyte Infusions (T-cell Receptor α/β Depleted Donor Lymphocyte Infusions)

QH101 (Allogeneic TCR-enhanced γδ T cell, Allogeneic TCR-enhanced γδ T cell(QH101))

IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells (IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells)

DS-1103a (DS-1103a)

SCG142 TCR-T cells (SCG142 TCR-T cells)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

pembrolizumab (Keytruda, Tebentafusp with Pembrolizumab)

TCR reserved and Power3 (SPPL3, TCR reserved and Power3, TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell)

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) peptide vaccine)

NEOK001 RDE (NEOK001 RDE)

LCB84 (LCB84)

Almonertinib/Furmonertinib/Osimertinib (third-generation EGFR TKIs, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib))

anti-PSMA CAR-NK (anti-PSMA CAR-NK)

LMP2 Antigen-specific TCR T cells (LMP2 Antigen-specific TCR T cells)

Docetetaxel (Docetetaxel)

anti-CTLA-4/PD-1 expressing EGFR-CAR-T (anti-CTLA-4/PD-1 expressing EGFR-CAR-T)

Autologous Anti-H3.3K27M TCR-expressing T-cells (Autologous Anti-H3.3K27M TCR-expressing T-cells)

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

bevacizumab, reference product (Avastin®, Avastin® (bevacizumab, reference product))

Multi-epitope (ME, Multi-epitope, Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine)

E7 TCR cells (E7 TCR cells)

Autologous WT1 TCR transduced T cells (Autologous WT1 TCR transduced T cells)

Capecitabine, Cetuximab, Oxaliplatin (Capecitabine, Cetuximab, Oxaliplatin)

ustekinumab (Stelara, 1: filgotinib 2: ustekinumab 3: vedolizumab 4: infliximab))

CT0590 CAR T Cells (CT0590 CAR T Cells)